Citius Pharmaceuticals (NASDAQ: CTXR)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.050 | -0.060 | -0.0100 | ||||
REV | 0 |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.050 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Citius Pharmaceuticals (NASDAQ: CTXR) through any online brokerage.
Other companies in Citius Pharmaceuticals’s space includes: Xeris Biopharma Holdings (NASDAQ:XERS), Satsuma Pharmaceuticals (NASDAQ:STSA), Terns Pharma (NASDAQ:TERN), Marinus Pharma (NASDAQ:MRNS) and Harrow Health (NASDAQ:HROW).
The latest price target for Citius Pharmaceuticals (NASDAQ: CTXR) was reported by HC Wainwright & Co. on Tuesday, January 18, 2022. The analyst firm set a price target for 6.00 expecting CTXR to rise to within 12 months (a possible 400.00% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Citius Pharmaceuticals (NASDAQ: CTXR) is $1.2 last updated August 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for Citius Pharmaceuticals.
Citius Pharmaceuticals’s Q3 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Citius Pharmaceuticals.
Citius Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.